CVS wins government funding for AI-assisted heart attack diagnosis tool
An algorithm that uses artificial intelligence to improve the diagnosis of heart attacks has been successful in the latest round of the Artificial Intelligence in Health and Care Award.
The Centre for Cardiovascular Science is one of 38 organisations to receive the funding, which was announced by the Health and Social Care Secretary Matt Hancock on 16 June 2021. The AI Award is making £140 million available over four years to accelerate the testing and evaluation of artificial intelligence technologies which meet the aims set out in the NHS Long Term Plan.
The Award means that the Centre for Cardiovascular Science will be able to develop an AI-guided tool to help doctors and nurses interpret patients’ troponin levels and diagnose heart attacks more accurately.
By developing the tool, the researchers aim to allow doctors and nurses working in the Emergency Department to accurately determine who needs to be admitted for further testing and who can be safely discharged home. The researchers anticipate the tool will help to rule-out heart attacks more quickly for these patients. This will help patients avoid unnecessary hospital admission and testing, and will result in cost-savings for the NHS. It will also help to rule-in heart attacks earlier and ensure prompt treatment in those patients likely to benefit most.
We are delighted to receive an AI Award to work on clinical decision making tools for myocardial infarction. Building on our work from the BHF-funded HighSTEACS project, we hope that the development of an AI-guided tool to diagnose heart attacks more accurately will ultimately improve the care that patients receive.
The AI Award is one of the programmes that make up the NHS AI Lab, led by NHSX and delivered in partnership with the Accelerated Access Collaborative (AAC) and National Institute for Health Research (NIHR).
Congratulations to the Centre for Cardiovascular Science on their success as one of our winners in Round 2 of the AI Award. We look forward to working with them as they develop and test their technology further, so that more patients can benefit from this cutting-edge artificial intelligence.